Metahexamide
Metahexamide (INN) is an anti-diabetic drug from the group of sulfonylureas. It is long-acting and belongs to the first-generation cyclohexyl-containing sulfonylureas. It was first described in 1959.[1]
Names | |
---|---|
Preferred IUPAC name
3-Amino-N-(cyclohexylcarbamoyl)-4-methylbenzene-1-sulfonamide | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.008.434 |
KEGG | |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
InChI
| |
SMILES
| |
Properties | |
Chemical formula |
C14H21N3O3S |
Molar mass | 311.4 g/mol |
Pharmacology | |
A10BB10 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references |
References
- Moss JM, Delawter D (September 1959). "Metahexamide in diabetes therapy". Ann NY Acad Sci. 82 (2): 614–7. doi:10.1111/j.1749-6632.1959.tb44940.x. PMID 14424617.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.